Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (BMY) carries a ŷRobot AI score of 69 out of 100. The model's fair value estimate is $63.39, 6.9% above the last close of $59.27. The chart signal reads Hold.
| Metric | BMY |
|---|---|
| AI score | 69 / 100 |
| Chart signal | Hold |
| Fair value estimate | $63.39 |
| Upside to fair value | 6.9% |
| Previous close | $59.27 |
| P/E | 13.74 |
| Price / sales | 2.55 |
| Market cap | $115.76B |
| EPS | 4.54 |
| Revenue growth | 2.0% |
| 1-year price change | 1.1% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about BMY
Is BMY overvalued or undervalued right now?
As of Oct 14, 2026, ŷRobot's fair-value model estimates Bristol-Myers Squibb Company (BMY) at $63.39 against a last close of $59.27, implying 6.9% upside to the model's estimate.
Is BMY's chart signal bullish or bearish?
The chart-signal model classifies BMY as Neutral as of Oct 14, 2026, with a signal score of 0.11 on a -1 to 1 scale.
What is BMY's ŷRobot AI score?
BMY scores 69 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 14, 2026.
Is BMY stock expensive on P/E and P/S?
BMY trades at 13.7 times earnings and 2.6 times sales as of Oct 14, 2026.
What does BMY's seasonal forecast show?
ŷRobot's seasonal forecast curve for BMY reads -0.4% at 30 days, +2.8% at 90 days, and +1.1% at one year as of Oct 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is BMY growing?
Bristol-Myers Squibb Company's revenue growth is +2.0% and free-cash-flow growth is +9.5% on the latest reported figures.
BMY chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.